CLDX
Celldex Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.35B
P/E Ratio
—
EPS
$-4.27
Beta
0.93
52W High
$35.79
52W Low
$19.52
50-Day MA
$31.95
200-Day MA
$27.75
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. The company is headquartered in Hampton, New Jersey.
Fundamentals
| Revenue (TTM) | 865,000 |
| Gross Profit (TTM) | $-264.60M |
| EBITDA | $-305.70M |
| Operating Margin | -562900.00% |
| Return on Equity | -48.90% |
| Return on Assets | -30.90% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $6.85 |
| Price-to-Book | 5.15 |
| Price-to-Sales (TTM) | 2837.51 |
| EV/Revenue | 2197.11 |
| EV/EBITDA | -17.34 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -97.80% |
| Shares Outstanding | $78.49M |
| Float | $72.46M |
| % Insiders | 0.27% |
| % Institutions | 94.89% |
Historical Volatility
HV 10-Day
53.02%
HV 20-Day
43.09%
HV 30-Day
41.80%
HV 60-Day
42.08%
HV Rank
11.9%
Volatility is currently expanding
Analyst Ratings
Consensus ($58.43 target)
2
Strong Buy12
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026